APO Research
Talk to an analyst

APO RESEARCH · REPORT

Small Molecule Multi-target Angiogenesis Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Small Molecule Multi-target Angiogenesis Inhibitor Market Outlook and Growth Opportunities 2026

27 December 2025195 pages

Choose your research edition.

Industry ResearchSmall Molecule Multi-target Angiogenesis Inhibitor Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Small Molecule Multi-target Angiogenesis Inhibitor Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Small Molecule Multi-target Angiogenesis Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Small Molecule Multi-target Angiogenesis Inhibitor Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Small Molecule Multi-target Angiogenesis Inhibitor Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Small Molecule Multi-target Angiogenesis Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Small Molecule Multi-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Small Molecule Multi-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Small Molecule Multi-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Small Molecule Multi-target Angiogenesis Inhibitor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Small Molecule Multi-target Angiogenesis Inhibitor market include Chia Tai Tianqing, Teva, Jiangsu Hengrui Pharmaceuticals, TWi Pharmaceuticals, Sanofi, Pfizer, Novartis, Janssen Biotech and Exelixis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Small Molecule Multi-target Angiogenesis Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Small Molecule Multi-target Angiogenesis Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Small Molecule Multi-target Angiogenesis Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Small Molecule Multi-target Angiogenesis Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

Small Molecule Multi-target Angiogenesis Inhibitor Segment by Company

Chia Tai Tianqing

Teva

Jiangsu Hengrui Pharmaceuticals

TWi Pharmaceuticals

Sanofi

Pfizer

Novartis

Janssen Biotech

Exelixis

Eisai

Boehringer Ingelheim

Bayer

AstraZeneca.

Small Molecule Multi-target Angiogenesis Inhibitor Segment by Type

Apatinib

Axitinib

Anlotinib

Vandetanib

Cabozantinib

Lenvatinib

Pazopanib

Sunitinib

Sorafenib

Other

Small Molecule Multi-target Angiogenesis Inhibitor Segment by Application

Cancer Therapy

Inflammatory and Autoimmune Diseases

Ophthalmic Diseases

Other

Small Molecule Multi-target Angiogenesis Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Small Molecule Multi-target Angiogenesis Inhibitor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Small Molecule Multi-target Angiogenesis Inhibitor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Small Molecule Multi-target Angiogenesis Inhibitor significant trends, drivers, influence factors in global and regions.

6. To analyze Small Molecule Multi-target Angiogenesis Inhibitor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Small Molecule Multi-target Angiogenesis Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Small Molecule Multi-target Angiogenesis Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Small Molecule Multi-target Angiogenesis Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Small Molecule Multi-target Angiogenesis Inhibitor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Small Molecule Multi-target Angiogenesis Inhibitor industry.

Chapter 3: Detailed analysis of Small Molecule Multi-target Angiogenesis Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Small Molecule Multi-target Angiogenesis Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Small Molecule Multi-target Angiogenesis Inhibitor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Small Molecule Multi-target Angiogenesis Inhibitor Industry Trends Table 2. Small Molecule Multi-target Angiogenesis Inhibitor Industry Drivers Table 3. Small Molecule Multi-target Angiogenesis Inhibitor Industry Opportunities and Challenges Table 4. Small Molecule Multi-target Angiogenesis Inhibitor Industry Restraints Table 5. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Share by Company (2021-2026) Table 7. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume Share by Company (2021-2026) Table 9. Global Small Molecule Multi-target Angiogenesis Inhibitor Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Small Molecule Multi-target Angiogenesis Inhibitor Company Ranking, (2024-2026) & (USD Million) Table 11. Global Small Molecule Multi-target Angiogenesis Inhibitor Key Company Manufacturing Base & Headquarters Table 12. Global Small Molecule Multi-target Angiogenesis Inhibitor Company, Product Type & Application Table 13. Global Small Molecule Multi-target Angiogenesis Inhibitor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Small Molecule Multi-target Angiogenesis Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Apatinib Table 18. Significant Companies of Axitinib Table 19. Significant Companies of Anlotinib Table 20. Significant Companies of Vandetanib Table 21. Significant Companies of Cabozantinib Table 22. Significant Companies of Lenvatinib Table 23. Significant Companies of Pazopanib Table 24. Significant Companies of Sunitinib Table 25. Significant Companies of Sorafenib Table 26. Significant Companies of Other Table 27. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Type (2021-2026) & (K Units) Table 29. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Type (2027-2032) & (K Units) Table 30. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume Share by Type (2021-2026) Table 31. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume Share by Type (2027-2032) Table 32. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Type (2021-2026) & (US$ Million) Table 34. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Type (2027-2032) & (US$ Million) Table 35. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type (2021-2026) Table 36. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type (2027-2032) Table 37. Significant Companies of Cancer Therapy Table 38. Significant Companies of Inflammatory and Autoimmune Diseases Table 39. Significant Companies of Ophthalmic Diseases Table 40. Significant Companies of Other Table 41. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 42. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Application (2021-2026) & (K Units) Table 43. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Application (2027-2032) & (K Units) Table 44. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume Share by Application (2021-2026) Table 45. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume Share by Application (2027-2032) Table 46. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Application (2021-2026) & (US$ Million) Table 48. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Application (2027-2032) & (US$ Million) Table 49. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application (2021-2026) Table 50. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application (2027-2032) Table 51. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 52. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2021-2026) & (K Units) Table 53. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region (2021-2026) Table 54. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2027-2032) & (K Units) Table 55. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region (2027-2032) Table 56. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Region (2021-2026) & (US$ Million) Table 58. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Region (2021-2026) Table 59. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Region (2027-2032) & (US$ Million) Table 60. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Region (2027-2032) Table 61. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Average Price (US$/Unit) by Region (2021-2026) Table 62. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Average Price (US$/Unit) by Region (2027-2032) Table 63. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 64. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 66. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2026) Table 67. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2027-2032) & (K Units) Table 68. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2027-2032) Table 69. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Country (2021-2026) & (US$ Million) Table 70. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Market Share by Country (2021-2026) Table 71. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Country (2027-2032) & (US$ Million) Table 72. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Market Share by Country (2027-2032) Table 73. Chia Tai Tianqing Company Information Table 74. Chia Tai Tianqing Business Overview Table 75. Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 77. Chia Tai Tianqing Recent Development Table 78. Teva Company Information Table 79. Teva Business Overview Table 80. Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Teva Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 82. Teva Recent Development Table 83. Jiangsu Hengrui Pharmaceuticals Company Information Table 84. Jiangsu Hengrui Pharmaceuticals Business Overview Table 85. Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 87. Jiangsu Hengrui Pharmaceuticals Recent Development Table 88. TWi Pharmaceuticals Company Information Table 89. TWi Pharmaceuticals Business Overview Table 90. TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 92. TWi Pharmaceuticals Recent Development Table 93. Sanofi Company Information Table 94. Sanofi Business Overview Table 95. Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 97. Sanofi Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 102. Pfizer Recent Development Table 103. Novartis Company Information Table 104. Novartis Business Overview Table 105. Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 107. Novartis Recent Development Table 108. Janssen Biotech Company Information Table 109. Janssen Biotech Business Overview Table 110. Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 112. Janssen Biotech Recent Development Table 113. Exelixis Company Information Table 114. Exelixis Business Overview Table 115. Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 117. Exelixis Recent Development Table 118. Eisai Company Information Table 119. Eisai Business Overview Table 120. Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 122. Eisai Recent Development Table 123. Boehringer Ingelheim Company Information Table 124. Boehringer Ingelheim Business Overview Table 125. Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 127. Boehringer Ingelheim Recent Development Table 128. Bayer Company Information Table 129. Bayer Business Overview Table 130. Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 132. Bayer Recent Development Table 133. AstraZeneca. Company Information Table 134. AstraZeneca. Business Overview Table 135. AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 137. AstraZeneca. Recent Development Table 138. Key Raw Materials Table 139. Raw Materials Key Suppliers Table 140. Small Molecule Multi-target Angiogenesis Inhibitor Distributors List Table 141. Small Molecule Multi-target Angiogenesis Inhibitor Customers List Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Small Molecule Multi-target Angiogenesis Inhibitor Product Image Figure 2. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 4. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Small Molecule Multi-target Angiogenesis Inhibitor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Apatinib Image Figure 10. Axitinib Image Figure 11. Anlotinib Image Figure 12. Vandetanib Image Figure 13. Cabozantinib Image Figure 14. Lenvatinib Image Figure 15. Pazopanib Image Figure 16. Sunitinib Image Figure 17. Sorafenib Image Figure 18. Other Image Figure 19. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume Share by Type (2021-2032) Figure 22. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type (2021-2032) Figure 25. Cancer Therapy Image Figure 26. Inflammatory and Autoimmune Diseases Image Figure 27. Ophthalmic Diseases Image Figure 28. Other Image Figure 29. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 30. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 31. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume Share by Application (2021-2032) Figure 32. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 34. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application (2021-2032) Figure 35. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 36. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 37. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 38. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 39. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 40. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 42. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 44. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 45. South America Small Molecule Multi-target Angiogenesis Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 46. South America Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 47. Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 48. Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 49. USA Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. USA Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. USA Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Canada Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Canada Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Canada Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Mexico Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Mexico Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Mexico Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Germany Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Germany Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Germany Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. France Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. France Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. France Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. U.K. Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. U.K. Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. U.K. Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Italy Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Italy Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Italy Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Spain Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Spain Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Spain Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Russia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Russia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Russia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Netherlands Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Netherlands Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Netherlands Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Nordic Countries Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Nordic Countries Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Nordic Countries Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. China Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. China Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. China Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Japan Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Japan Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Japan Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. South Korea Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. South Korea Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. South Korea Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. India Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. India Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. India Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Australia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Australia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Australia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Southeast Asia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Southeast Asia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Southeast Asia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Brazil Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Brazil Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Brazil Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Argentina Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Argentina Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Argentina Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Chile Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Chile Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Chile Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Colombia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Colombia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Colombia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Peru Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Peru Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Peru Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Saudi Arabia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Saudi Arabia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Saudi Arabia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Israel Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Israel Arabia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Israel Arabia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. UAE Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. UAE Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. UAE Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Turkey Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Turkey Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Turkey Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Iran Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 128. Iran Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 129. Iran Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 130. Egypt Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 131. Egypt Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 132. Egypt Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 133. Small Molecule Multi-target Angiogenesis Inhibitor Value Chain Figure 134. Manufacturing Cost Structure Figure 135. Small Molecule Multi-target Angiogenesis Inhibitor Sales Mode & Process Figure 136. Direct Comparison with Distribution Share Figure 137. Distributors Profiles Figure 138. Years Considered Figure 139. Research Process Figure 140. Key Executives Interviewed

Scope & coverage.

Types
  • Apatinib
  • Axitinib
  • Anlotinib
  • Vandetanib
  • Cabozantinib
  • Lenvatinib
  • Pazopanib
  • Sunitinib
  • Sorafenib
  • Other
Applications
  • Cancer Therapy
  • Inflammatory and Autoimmune Diseases
  • Ophthalmic Diseases
  • Other
Companies covered
  • Chia Tai Tianqing
  • Teva
  • Jiangsu Hengrui Pharmaceuticals
  • TWi Pharmaceuticals
  • Sanofi
  • Pfizer
  • Novartis
  • Janssen Biotech
  • Exelixis
  • Eisai
  • Boehringer Ingelheim
  • Bayer
  • AstraZeneca.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value (2021-2032)
  4. 1.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume (2021-2032)
  5. 1.2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Small Molecule Multi-target Angiogenesis Inhibitor Market Dynamics
  1. 2.1 Small Molecule Multi-target Angiogenesis Inhibitor Industry Trends
  2. 2.2 Small Molecule Multi-target Angiogenesis Inhibitor Industry Drivers
  3. 2.3 Small Molecule Multi-target Angiogenesis Inhibitor Industry Opportunities and Challenges
  4. 2.4 Small Molecule Multi-target Angiogenesis Inhibitor Industry Restraints
3 Small Molecule Multi-target Angiogenesis Inhibitor Market by Company
  1. 3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Company Revenue Ranking in 2025
  2. 3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Company (2021-2026)
  3. 3.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Company (2021-2026)
  4. 3.4 Global Small Molecule Multi-target Angiogenesis Inhibitor Average Price by Company (2021-2026)
  5. 3.5 Global Small Molecule Multi-target Angiogenesis Inhibitor Company Ranking (2024-2026)
  6. 3.6 Global Small Molecule Multi-target Angiogenesis Inhibitor Company Manufacturing Base and Headquarters
  7. 3.7 Global Small Molecule Multi-target Angiogenesis Inhibitor Company Product Type and Application
  8. 3.8 Global Small Molecule Multi-target Angiogenesis Inhibitor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Small Molecule Multi-target Angiogenesis Inhibitor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Small Molecule Multi-target Angiogenesis Inhibitor Market by Type
  1. 4.1 Small Molecule Multi-target Angiogenesis Inhibitor Type Introduction
  2. 4.1.1 Apatinib
  3. 4.1.2 Axitinib
  4. 4.1.3 Anlotinib
  5. 4.1.4 Vandetanib
  6. 4.1.5 Cabozantinib
  7. 4.1.6 Lenvatinib
  8. 4.1.7 Pazopanib
  9. 4.1.8 Sunitinib
  10. 4.1.9 Sorafenib
  11. 4.1.10 Other
  12. 4.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Type
  13. 4.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Type (2021-2032)
  15. 4.2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume Share by Type (2021-2032)
  16. 4.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Type
  17. 4.3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Type (2021 VS 2025 VS 2032)
  18. 4.3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Type (2021-2032)
  19. 4.3.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type (2021-2032)
5 Small Molecule Multi-target Angiogenesis Inhibitor Market by Application
  1. 5.1 Small Molecule Multi-target Angiogenesis Inhibitor Application Introduction
  2. 5.1.1 Cancer Therapy
  3. 5.1.2 Inflammatory and Autoimmune Diseases
  4. 5.1.3 Ophthalmic Diseases
  5. 5.1.4 Other
  6. 5.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Application
  7. 5.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Application
  11. 5.3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Application (2021-2032)
  13. 5.3.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application (2021-2032)
6 Small Molecule Multi-target Angiogenesis Inhibitor Regional Sales and Value Analysis
  1. 6.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2021-2026
  4. 6.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2027-2032)
  5. 6.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Region (2021-2032)
  7. 6.4.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Region: 2021-2026
  8. 6.4.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Region (2027-2032)
  9. 6.5 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Value (2021-2032)
  12. 6.6.2 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Value (2021-2032)
  15. 6.7.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Small Molecule Multi-target Angiogenesis Inhibitor Sales Value (2021-2032)
  21. 6.9.2 South America Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Country, 2025 VS 2032
7 Small Molecule Multi-target Angiogenesis Inhibitor Country-level Sales and Value Analysis
  1. 7.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2032)
  4. 7.3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026)
  5. 7.3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2027-2032)
  6. 7.4 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Country (2021-2032)
  7. 7.4.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Country (2021-2026)
  8. 7.4.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Small Molecule Multi-target Angiogenesis Inhibitor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing
  2. 8.1.1 Chia Tai Tianqing Company Information
  3. 8.1.2 Chia Tai Tianqing Business Overview
  4. 8.1.3 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Jiangsu Hengrui Pharmaceuticals
  14. 8.3.1 Jiangsu Hengrui Pharmaceuticals Company Information
  15. 8.3.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  16. 8.3.3 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  18. 8.3.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  19. 8.4 TWi Pharmaceuticals
  20. 8.4.1 TWi Pharmaceuticals Company Information
  21. 8.4.2 TWi Pharmaceuticals Business Overview
  22. 8.4.3 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  24. 8.4.5 TWi Pharmaceuticals Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Janssen Biotech
  44. 8.8.1 Janssen Biotech Company Information
  45. 8.8.2 Janssen Biotech Business Overview
  46. 8.8.3 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  48. 8.8.5 Janssen Biotech Recent Developments
  49. 8.9 Exelixis
  50. 8.9.1 Exelixis Company Information
  51. 8.9.2 Exelixis Business Overview
  52. 8.9.3 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  54. 8.9.5 Exelixis Recent Developments
  55. 8.10 Eisai
  56. 8.10.1 Eisai Company Information
  57. 8.10.2 Eisai Business Overview
  58. 8.10.3 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  60. 8.10.5 Eisai Recent Developments
  61. 8.11 Boehringer Ingelheim
  62. 8.11.1 Boehringer Ingelheim Company Information
  63. 8.11.2 Boehringer Ingelheim Business Overview
  64. 8.11.3 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  66. 8.11.5 Boehringer Ingelheim Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 AstraZeneca.
  74. 8.13.1 AstraZeneca. Company Information
  75. 8.13.2 AstraZeneca. Business Overview
  76. 8.13.3 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  78. 8.13.5 AstraZeneca. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Small Molecule Multi-target Angiogenesis Inhibitor Value Chain Analysis
  2. 9.1.1 Small Molecule Multi-target Angiogenesis Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Small Molecule Multi-target Angiogenesis Inhibitor Sales Mode & Process
  6. 9.2 Small Molecule Multi-target Angiogenesis Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Small Molecule Multi-target Angiogenesis Inhibitor Distributors
  9. 9.2.3 Small Molecule Multi-target Angiogenesis Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst